Challenges of modelling TDP-43 pathology in mice
Mammalian Genome · 2025
DOI: 10.1007/s00335-025-10131-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Mammalian Genome, 2025. Verfasst von José Miguel Brito Armas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Investigación Hospital Universitario de Canarias, Instituto de Investigación Sanitaria de Canarias, CIBERNED and ITB-ULL, Tenerife, Spain. Hauptthemen laut MEDLINE: DNA-Binding Proteins, Disease Models, Animal, TDP-43 Proteinopathies. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
TDP-43 is a normally nuclear RNA binding protein that under pathological conditions may be excluded from the nucleus and deposited in the cytoplasm in the form of insoluble polyubiquitinated and polyphosphorylated inclusions. This nuclear exclusion coupled with cytoplasmic accumulation is called TDP-43 pathology and contributes to a range of disorders collectively known as TDP-43 proteinopathies. These include the great majority of amyotrophic lateral sclerosis (ALS) cases, all limbic-predominant age-related TDP-43 encephalopathy (LATE), as well as up to 50% of frontotemporal lobar degeneration (FTLD) and Alzheimer’s disease (AD) cases. Thus, TDP-43 pathology is a common feature underlying a wide range of neurodegenerative conditions. However, modelling it has proven to be challenging, particularly generating models with concomitant TDP-43 loss of nuclear function and cytoplasmic inclusions. Here, focussing exclusively on mice, we discuss TDP-43 genetic models in terms of the presence of TDP-43 pathology, and we consider other models with TDP-43 pathology due to mutations in disparate genes. We also consider manipulations aimed at producing TDP-43 pathology, and we look at potential strategies to develop new, much needed models to address the many outstanding questions regarding how and why TDP-43 protein leaves the nucleus and accumulates in the cytoplasm, causing downstream dysfunction and devastating disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Unidad de Investigación Hospital Universitario de Canarias, Instituto de Investigación Sanitaria de Canarias, CIBERNED and ITB-ULL, Tenerife, Spain.
- Department of Neuromuscular Diseases and Queen Square Motor Neuron Disease Centre, UCL Queen Square Institute of Neurology, London, UK. elizabeth.fisher@ucl.ac.uk.
- Unidad de Investigación Hospital Universitario de Canarias, Instituto de Investigación Sanitaria de Canarias, CIBERNED and ITB-ULL, Tenerife, Spain. aacevedo@ull.edu.es.
Zitieren
APA
Armas, J. M. B., Taoro-González, L., Fisher, E. M. C., & Acevedo-Arozena, A. (2025). Challenges of modelling TDP-43 pathology in mice. Mammalian Genome. https://doi.org/10.1007/s00335-025-10131-1
Vancouver
Armas JMB, Taoro-González L, Fisher EMC, Acevedo-Arozena A. Challenges of modelling TDP-43 pathology in mice. Mammalian Genome. 2025. doi:10.1007/s00335-025-10131-1
BibTeX
@article{Armas2025,
author = {Armas, José Miguel Brito and Taoro-González, Lucas and Fisher, Elizabeth M C and Acevedo-Arozena, Abraham},
title = {Challenges of modelling TDP-43 pathology in mice},
journal = {Mammalian Genome},
year = {2025},
doi = {10.1007/s00335-025-10131-1}
}
EUVIMED